Innovative Product Somahlution's flagship product, DuraGraft, offers a unique vascular graft treatment that enhances clinical outcomes and reduces graft failure complications, positioning the company as a leader in specialized medical devices for vascular surgery.

Recent Acquisition Following its acquisition by Marizyme in December 2020, Somahlution benefits from expanded resources and a broader strategic network, creating opportunities to leverage additional sales channels and forge partnerships within the medical device and biotech sectors.

Growth Potential With revenue estimates between 10 to 25 million dollars and a niche focus on vascular grafts, Somahlution presents a promising opportunity for companies seeking to enter or expand within the specialized medical technology market.

Technological Stack Utilizing advanced web and data technologies such as MySQL, PHP, and Nginx, Somahlution demonstrates a commitment to robust digital infrastructure, indicating potential for scalable technology partnerships or integrations.

Market Focus Operating primarily outside the U.S. market, Somahlution is well-positioned to capture international demand for innovative vascular treatment solutions, presenting a strategic opportunity for exporters and global medical device distributers.